CPT® Code 90746

The CPT® Code 90746 refers to the Hepatitis B vaccine (HepB) specifically formulated for adult patients, administered in a three-dose schedule via intramuscular injection. Vaccines, unlike immune globulins that offer short-term, passive immunity, are designed to provide active, long-term immunity. This is achieved by introducing altered versions of specific viruses or bacteria into the recipient's immune system, prompting it to produce its own antibodies against the pathogens. The immune system retains a memory of these antibodies, enabling a quicker and more effective response upon subsequent exposures to the same antigens. The hepatitis B vaccine is crucial in preventing chronic liver disease, which can lead to severe health complications, including hospitalization and death. Additionally, it plays a significant role in reducing the risk of long-term consequences such as hepatocellular carcinoma, marking it as one of the pioneering cancer vaccines in medical use. The vaccine can be derived from the blood plasma of asymptomatic carriers or synthesized through recombinant technology, where a plasmid containing the hepatitis gene is inserted into common baker's yeast. This yeast is then lysed, and the components are purified for use. It is important to note that the codes associated with the hepatitis B vaccine, including CPT® Code 90746, specifically report the vaccine product for intramuscular use, while the actual injection procedure is reported separately. Other related codes include 90739 for a 2-dose or 4-dose schedule of CpG-adjuvanted HepB vaccine, 90740 for dialysis or immunosuppressed patients in a 3-dose schedule, 90743 for an adolescent 2-dose schedule, and 90744 for a pediatric/adolescent 3-dose schedule. Additionally, CPT® Code 90747 is designated for dosage in dialysis or immunosuppressed patients following a 4-dose schedule.